Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 6/20 | 0.33 |
| ▸ | KAT2B | Q92831 | 4/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.32 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.32 |
| ▸ | JAK2 | O60674 | 1/20 | 0.32 |
| ▸ | JAK1 | P23458 | 1/20 | 0.32 |
| ▸ | TYK2 | P29597 | 1/20 | 0.32 |
| ▸ | PDCD1 | Q15116 | 3/20 | 0.31 |
| ▸ | CD274 | Q9NZQ7 | 3/20 | 0.31 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.31 |
| ▸ | ALOX5 | P09917 | 4/20 | 0.31 |
| ▸ | ATR | Q13535 | 1/20 | 0.31 |
| ▸ | ATRIP | Q8WXE1 | 1/20 | 0.31 |
| ▸ | NSD2 | O96028 | 1/20 | 0.31 |
| ▸ | SETDB1 | Q15047 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29355641 | 0.73 | JAK3 (0.42) | JAK3ADORA1 | |
| SCHEMBL6500066 | 0.70 | JAK3 (0.41) | JAK3ADORA1JAK2 | |
| SCHEMBL4524341 | 0.68 | HTR3E (0.49) | — | |
| SCHEMBL942469 | 0.67 | PIK3CB (0.51) | JAK3 | |
| SCHEMBL6066498 | 0.66 | ROCK2 (0.38) | JAK3 | |
| SCHEMBL10580164 | 0.65 | — | — | |
| SCHEMBL592718 | 0.63 | — | — | |
| SCHEMBL18075990 | 0.63 | MAP3K5 (0.43) | — | |
| SCHEMBL31609349 | 0.63 | KDM4E (0.46) | — | |
| SCHEMBL5709843 | 0.63 | KDM4E (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017180592-A1 | SEQUENCE DESIGN FOR EFFICIENT ASSEMBLY OF NUCLEIC ACID STRUCTURES | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2017-10-19 | — | — | WO | disclosed |
| WO-2017100251-A1 | TARGET DETECTION USING BARCODE CONJUGATES AND NUCLEIC ACID NANOARRAYS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2017-06-15 | — | — | WO | disclosed |
| EP-3145859-A2 | SCALABLE NUCLEIC ACID-BASED NANOFABRICATION | President and Fellows of Harvard College (US) | 2017-03-29 | — | — | EP | disclosed |
| WO-2017049136-A1 | NUCLEIC ACID FRAMEWORKS FOR STRUCTURAL DETERMINATION | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2017-03-23 | — | — | WO | disclosed |
| CN-106488883-A | Scalable nucleic acid-based nano-fabrication | 哈佛学院院长及董事 | 2017-03-08 | — | — | CN | disclosed |
| CN-103025351-B | Comprise cholesterol and the vaccine of the CPG as unique adjuvant-supporting agent molecule | 佐蒂斯比利时股份有限公司 | 2016-08-24 | — | — | CN | disclosed |
| CN-102245198-B | IgE CH3 peptide vaccine | 辉瑞疫苗有限责任公司 | 2016-08-17 | — | — | CN | disclosed |
| CN-105705143-A | Nucleic acid nanostructures for in vivo agent delivery | 达娜-法勃肿瘤研究所公司 | 2016-06-22 | — | — | CN | disclosed |
| CN-102596236-B | Antigenic Tau peptides and uses thereof | PFIZER VACCINES LLC | 2015-06-24 | — | — | CN | disclosed |
| CN-102333538-B | Immunostimulatory oligonucleotides | PFIZER | 2014-01-15 | — | — | CN | disclosed |
| CN-102245198-A | IgE CH3 peptide vaccine | PFIZER VACCINES LLC | 2011-11-16 | — | — | CN | disclosed |
| EP-2376107-A1 | IMMUNOSTIMULATORY OLIGONUCLEOTIDES | Coley Pharmaceutical Group, Inc. (US) | 2011-10-19 | — | — | EP | disclosed |
| WO-2010067262-A1 | IMMUNOSTIMULATORY OLIGONUCLEOTIDES | PFIZER INC. (US) | 2010-06-17 | — | — | WO | disclosed |
| EP-2160199-A2 | CLASS A OLIGONUCLEOTIDES WITH IMMUNOSTIMULATORY POTENCY | Coley Pharmaceutical Group, Inc. (US) | 2010-03-10 | — | — | EP | disclosed |
| CN-101340931-A | Modulation of tlr-mediated immune responses using adaptor oligonucleotides | COLEY PHARM GMBH (DE) | 2009-01-07 | — | — | CN | disclosed |
| WO-2008142509-A2 | CLASS A OLIGONUCLEOTIDES WITH IMMUNOSTIMULATORY POTENCY | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2008-11-27 | — | — | WO | disclosed |
| CN-101193646-A | Methods for treating infectious disease exacerbated asthma | COLEY PHARM GROUP INC (US) | 2008-06-04 | — | — | CN | disclosed |
| EP-1776105-A2 | METHODS AND COMPOSITIONS FOR INDUCING INNATE IMMUNE RESPONSES | Coley Pharmaceutical Group, Ltd (CA) | 2007-04-25 | — | — | EP | disclosed |
| WO-2006134423-A2 | METHODS AND COMPOSITIONS FOR INDUCING INNATE IMMUNE RESPONSES | COLEY PHARMACEUTICAL GROUP, LTD. (CA) | 2006-12-21 | — | — | WO | disclosed |
| CN-1753687-A | Use of cpg oligonucleotides in the treatment of hepatitis c virus infection | COLEY PHARMACEUTICAL GROUP LTD (CA) | 2006-03-29 | — | — | CN | disclosed |